



Therapix Biosciences signs TS with one of the world's largest THC producers

Rhodes Technologies, a Purdue Pharma group company, will supply Therapix with API for the R&D activity, in consideration for a future exclusive supply right and a right of negotiation to marketing the product in the U.S.

Therapix Biosciences, a company engaged in the development of cannabinoid-based drugs, announces that it has signed an unbinding term-sheet with Rhodes Technologies, a Purdue Pharma group company, which is one of the leading producers of synthetic THC in the U.S. The agreement refers to a product that the Company intends to develop, a cannabinoid tablet containing an ultra-low dosage of THC for the treatment of mild cognitive impairment.

According to the term-sheet, Rhodes Technologies will supply the Company, at its expense, with a quantity of API (active pharmaceutical ingredient) for conducting the research and development of the pipeline product, and in consideration therefor, the Company shall grant Rhodes Technologies an exclusive right to supply the API for the finished drug product and a right of first negotiation for the marketing and commercialization of the product in the U.S.

In the Company's estimation, the term-sheet with Rhodes Technologies will serve as basis for a strategic collaboration with one of the most prominent companies in the field, thus reinforcing the Company's intentions of focusing its business strategy on the creation and expansion of a portfolio of technologies and assets in the field of cannabinoid-based treatments, further to a number of projects in which the Company has chosen to engage and focus on in recent months.

Dr. Elran Haber, the Company's CEO, stated that "we are pleased with the increasing interest shown by leading companies in the field. The term-sheet constitutes a vote of confidence in the Company's technologies and products, we are advancing with the necessary preparations towards clinical trials in humans and continuing our research and development efforts".

About Therapix

Therapix Biosciences Ltd., is a biopharmaceutical company focused on identifying and investing in promising technologies in the biopharmaceutical field, while placing an emphasis on technologies that are based on a known biological mechanism which has passed the proof-of-concept phase, and which provide a solution for significant medical needs in the market and involve an investment of up to \$2 million for achieving a material milestone. The Company focuses on the creation and expansion of a portfolio of

technologies and assets in the field of treatments based on cannabinoids (active compounds in the cannabis plant), and is currently examining the advancement of research and development programs of a cannabinoid-based medical product for treating Tourette's syndrome (under an orphan drug designation) as well as additional cognitive disorders.